GlassScriptPhysician profile
Jay R Arthur
NPI 1083970040
$7,903.82
in general payments reported to CMS, 2019-2025
27 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,734 · 2022: $1,518 · 2023: $1,727 · 2024: $1,287 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,629 · Education: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,628.52 |
| Education | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,382.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $704.47 | 2022-2025 | |
| Genzyme Corporation | $693.65 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $677.65 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $638.79 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $573.60 | 2021-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $404.33 | 2021-2025 | Tremfya |
| Ucb, INC. | $212.65 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $212.47 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $205.41 | 2023 | Vtama |
| Incyte Corporation | $194.76 | 2021-2025 | Opzelura |
| Stryker Corporation | $164.44 | 2021 | |
| Almirall LLC | $131.28 | 2021-2023 | Seysara |
| Galderma Laboratories, L.P. | $123.66 | 2021-2025 | Nemluvio, Aklief |
| Avanos Medical | $99.75 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $98.94 | 2022-2025 | |
| Leo Pharma INC. | $71.34 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $67.37 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $48.01 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.79 | 2023-2024 | Spevigo, Cyltezo |
| Genentech USA, INC. | $37.25 | 2021-2022 | |
| Organon LLC | $35.18 | 2023-2025 | Vtama |
| Botanix Sb INC | $32.74 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $18.32 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.92 | 2022 | |
| Biofrontera INC. | $8.58 | 2021 | |
| Mayne Pharma Commercial LLC | $7.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.